<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868022</url>
  </required_header>
  <id_info>
    <org_study_id>117360</org_study_id>
    <nct_id>NCT01868022</nct_id>
  </id_info>
  <brief_title>Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling</brief_title>
  <official_title>Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with
      malignancies with abnormal dependence on FGF pathway signaling. Combination doses of
      GSK3052230 with standard of care chemotherapy in the first and second line or greater setting
      of metastatic squamous non-small cell lung cancer (NSCLC) and first line malignant pleural
      mesothelioma subjects will be studied in the 3+3 dose-escalation design. This will be a
      multi-arm, multicenter, non-randomized, parallel-group, uncontrolled, open-label Phase IB
      study designed to evaluate the safety, tolerability and preliminary activity of GSK3052230 in
      combination with paclitaxel + carboplatin (Arm A), in combination with docetaxel (Arm B), or
      in combination with pemetrexed + cisplatin (Arm C). Approximately 70 subjects will be
      enrolled in the study (approximately up to 120 may be enrolled).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2013</start_date>
  <completion_date type="Actual">October 24, 2017</completion_date>
  <primary_completion_date type="Actual">October 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and severity of adverse events (AEs) as a measure of safety and tolerability</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>AEs will be collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice. Severity of AEs will be graded utilizing the National Cancer Institute- Common Terminology Criteria for AEs (NCI-CTCAE) version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants withdrawn due to AEs as measure of safety and tolerability</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose interruptions and reduction as a measure of safety and tolerability</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment duration as a measure of safety and tolerability</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) as a measure of safety and tolerability</measure>
    <time_frame>Cycle 1 (first 21 days of study treatment).</time_frame>
    <description>DLT: Toxicity due to GSK3052230 its combination with chemotherapy within Cycle 1 that are unlikely to be due to another cause ( known effects of cytotoxic chemotherapy, disease progression, or accident according to the following criteria: Grade 3 or 4 clinically significant non-hematological toxicity, Grade 4 neutropenia lasting more than 7 days, Grade 4 febrile Neutropenia, Grade 4 thrombocytopenia, Grade 4 clinically significant lab abnormalities with duration greater than 48hrs, Treatment delay of 14 days or greater due to unresolved drug-related toxicity, and any grade 2 toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital sign as a measure of safety and tolerability</measure>
    <time_frame>Baseline and Day 1 of each treatment cycle (Up to 6 months).</time_frame>
    <description>Vital signs include: systolic blood pressure, diastolic blood pressure, temperature, respiration rate and pulse rate. Vital signs will be measured after subject resting for at least 5 minutes in a semi-supine position.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in 12-lead electrocardiogram (ECG) as a measure of safety and tolerability</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>12-lead ECGs will be obtained at designated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Echocardiogram (ECHO) as measure of safety and tolerability</measure>
    <time_frame>Baseline and Cycle 4 (Day 60).</time_frame>
    <description>ECHOs will be performed at baseline to assess cardiac ejection fraction and cardiac valve morphology for the purpose of study eligibility and Cycle 4. Evaluation of ECHO will include evaluation for left ventricular ejection fraction (LVEF) and both right and left-sided valvular lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in laboratory test as measure of safety and tolerability</measure>
    <time_frame>Baseline and up to 6 months</time_frame>
    <description>Laboratory parameters include: hematology, urinalysis, clinical chemistry and additional parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) or maximum feasible dose (MFD) of GSK3052230 in arm A and B</measure>
    <time_frame>21 days</time_frame>
    <description>The MTD for the combination regimens in Arm A and B will be defined as the highest dose level tested at which &lt;33% of subjects experience a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Best response defined as complete or partial response, stable disease or progressive disease according to RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) per RECIST 1.1 or modified RECIST</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>ORR defined as the proportion of subjects with investigator-assessed confirmed complete response or partial response per RECIST 1.1 or modified RECIST for Malignant pleural mesothelioma (MPM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in physical examination parameters</measure>
    <time_frame>Baseline and Up to follow up visit (7 months).</time_frame>
    <description>Physical examinations include will include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. Height and weight will also be measured and recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) by investigator assessment per RECIST 1.1 or modified RECIST</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>PFS is defined as the interval between first dose of GSK3052230 and the earliest date of disease progression or death due to any cause by investigator assessment per RECIST 1.1 or modified RECIST for MPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK3052230 population pharmacokinetic (PK) profile</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>GSK3052230 population PK parameters include: systemic clearance of parent drug (CL) and apparent volume of distribution after IV administration (Vd), and relevant covariates which may influence exposure (e.g. age, weight, or disease related covariates)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Forced Vital Capacity (FVC) in subjects with MPM</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>FVC will be measured to to assess improvement in pulmonary function in subject with MPM in arm C only</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A: GSK3052230 + paclitaxel/carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: GSK3052230 + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: GSK3052230 + pemetrexed and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3052230</intervention_name>
    <description>A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.</description>
    <arm_group_label>Arm A: GSK3052230 + paclitaxel/carboplatin</arm_group_label>
    <arm_group_label>Arm C: GSK3052230 + pemetrexed and cisplatin</arm_group_label>
    <arm_group_label>Arm B: GSK3052230 + docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitaxel will be from commercial stock.</description>
    <arm_group_label>Arm A: GSK3052230 + paclitaxel/carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin will be from commercial stock.</description>
    <arm_group_label>Arm A: GSK3052230 + paclitaxel/carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel will be from commercial stock.</description>
    <arm_group_label>Arm B: GSK3052230 + docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>pemetrexed will be from commercial stock</description>
    <arm_group_label>Arm C: GSK3052230 + pemetrexed and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin will be from commercial stock</description>
    <arm_group_label>Arm C: GSK3052230 + pemetrexed and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Signed written informed consent

          -  Histologically or cytologically confirmed diagnosis: Arm A and B- stage IV recurrent
             metastatic squamous NSCLC with Fibroblast growth factor receptor 1 (FGFR1) gene
             amplification by central laboratory testing. Arm C- recurrent after local therapy or
             unresectable MPM with measurable lesions.

        For specific arms the following requirements:

        Arm A: Subjects who have received no prior therapy for Stage IIIB or Stage IV or recurrent
        metastatic disease. Note, to avoid any undue delay of initiating systemic chemotherapy for
        these subjects with newly diagnosed metastatic disease, it is allowed to initiate the first
        cycle of chemotherapy while eligibility for the study is still being determined, as long as
        the first dose of GSK3052230 is given no later than Cycle 2 Day 1 of chemotherapy. In
        addition, subjects with Stage IIIB or Stage IV disease and recurrence after previous NSCLC
        that has been treated with surgery and adjuvant chemotherapy or a radio- chemotherapy
        regimen with curative intent are eligible, provided 6 months has passed since this
        treatment ended.

        Arm B: Subjects who have documented tumor progression (based on radiological imaging) or
        intolerability after receiving at least one prior line of platinum containing combination
        chemotherapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note: Prior
        treatment should not include docetaxel but may have included paclitaxel.

        Arm C: Subjects who have received no prior systemic therapy for MPM.

        - Availability of archival tumor tissue required for assessment of deregulated FGF pathway
        signalling, but not limited to, FGFR1 amplification or FGF2 or FGFR1 expression. If
        archival tissue is not available, a fresh biopsy is required. In Arms A and B, subjects
        will be prospectively screened for FGFR1 gene amplification using a Fluorescence in situ
        hybridization (FISH) assay for the dose expansion and the MTD/MFD cohorts only. For
        inclusion in this study, based on the central laboratory testing, FGFR1 gene amplification
        must meet one of the following criteria: a ratio of FGFR1/CEN 8 of &gt;=2; or average number
        of FGFR1 signals per tumor nucleus of &gt;=6; or the percentage of tumor nuclei containing &gt;=5
        FGFR1 signals is &gt;=50%.

        In Arm C, FGF2 expression by IHC will be evaluated retrospectively in tissue samples by a
        central laboratory and is not a requirement for study entry.

          -  Measurable disease per RECIST version 1.1 (Arm A and B) and modified RECIST for Arm C.

          -  Male or female &gt;=18 years of age.

          -  Women of childbearing potential must have a negative serum pregnancy test within 7
             days of first dose of study treatment and agree to use effective contraception, from
             14 days prior to the first dose of study treatment, throughout the study, and for 6
             months following the last dose of chemotherapy or 4 weeks after the last dose of
             GSK3052230, whichever is latest. .

          -  Men with a female partner of childbearing potential must have either had a prior
             vasectomy or agree to use effective contraception for at least 2 weeks prior to
             administration of the first dose of study treatment and for at least 6 months after
             the last dose of chemotherapy to allow for clearance of any altered sperm.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 for Arm A and C
             subjects and 0-2 for Arm B.

          -  French subjects: In France, a subject will be eligible for inclusion in this study
             only if either affiliated to or a beneficiary of a social security category

          -  Must have adequate organ function as defined by the following baseline values:
             Absolute neutrophil count &gt;=1.5 x 10^9/Liter, Hemoglobin &gt;=9 gram (g)/decilitre(dL),
             Platelets &gt;=100 x 10^9/L, Partial thromboplastin time (PTT) &lt;=1.25 x upper limit of
             normal (ULN), Albumin &gt;=2.5 g/dL, Serum total bilirubin &lt;=1.25 times ULN (for Arm B:
             &lt;=ULN ), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) &lt;=2.5
             times ULN (for Arm B: &lt;=1.5 times ULN), Serum Creatinine &lt;=1.5 x ULN, Or Measured or
             Calculated Creatinine Clearance &gt;=45 mL/min (Arm A or B), &gt;=65 mL/min (Arm C), Left
             ventricular ejection fraction &gt;=50% by ECHO.

        Exclusion Criteria

          -  For Arms A and C: Treatment with any FGFR inhibitor. For Arm B: Treatment with any
             anti-cancer therapy (for biological anti-cancer therapies see criteria below) during
             the preceding 4 weeks or within 4 half-lives of the therapy, whichever is longer.

          -  Receipt of any biological therapy within 6 weeks of the first dose of GSK3052230

          -  Unresolved toxicity of National Cancer Institute Common Terminology Criteria for
             Adverse Events, version 4.03 (NCI CTCAE version 4.03) Grade 2 or higher from previous
             anti-cancer therapy, except alopecia.

          -  Active malignancy other than the cancer under study. Subjects with a history of
             completely resected non-melanomatous skin carcinoma or successfully treated in situ
             carcinoma are eligible.

          -  Presence of uncontrolled infection

          -  Prior major surgery or trauma within 28 days before first dose of study drug

          -  Presence of any non-healing wound, fracture, or ulcer

          -  Any prohibited medication(s) as described in protocol

          -  Conditions likely to increase the potential for abdominal perforation or fistula
             formation, including but not limited to:

        Luminal intestinal cancers or bulky abdominal disease. Presence or history of abdominal
        fistula, gastrointestinal perforation, peptic ulcer disease or intra-abdominal abscess
        within the six months prior to the first dose of GSK3052230.

        Other risk factors for perforation, such as acute diverticulitis, obstruction or previous
        abdominal or pelvic radiation.

          -  Symptomatic leptomeningeal or brain metastases or spinal cord compression Note:
             Subjects previously treated for these conditions are eligible if they meet both of the
             criteria below: (1) have had stable CNS disease for at least 4 weeks after local
             therapy as assessed by imaging (contrast enhanced magnetic resonance imaging [MRI] or
             computed tomography [CT]) prior to Day 1, and (2) are asymptomatic and off
             corticosteroids, or are on stable dose of corticosteroids for at least 4 weeks prior
             to Day 1.

          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to study drugs (GSK3052230, docetaxel, paclitaxel, carboplatin,
             pemetrexed, cisplatin) and or their excipients that contraindicate their
             participation.

          -  Known human immunodeficiency virus-positive serology, acquired immunodeficiency
             syndrome (AIDS), or an AIDS-related illness.

          -  Prior organ or allogeneic stem cell transplant

          -  The following cardiac abnormalities:

        Corrected QT (QTc) interval &gt;=480 millisecond. History of acute coronary syndromes
        (including unstable angina) within the past 24 weeks Coronary angioplasty or stenting
        within the past 24 weeks. Class II, III, or IV heart failure as defined by the New York
        Heart Association (NYHA) functional classification system.

        Abnormal cardiac valve morphology (&gt;= Grade 2) documented by echocardiogram (subjects with
        Grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study).

        History of known arrhythmias (except sinus arrhythmia and atrial fibrillation that is
        controlled) within the past 24 weeks.

          -  Presence or history of hemoptysis (&gt;1/2 teaspoon of red blood) 2 weeks prior to the
             first dose of GSK3052230

          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other
             conditions that could interfere with subject's safety, obtaining informed consent or
             compliance to the study procedures.

          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or
             asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease
             per investigator's assessment).

          -  Pregnant, lactating or actively breast feeding females.

          -  French subjects: The French subject has participated in any study using an
             investigational study treatment(s) during the previous 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koebenhavn Oe</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115 478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197 089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGFR1</keyword>
  <keyword>FP1039</keyword>
  <keyword>GSK3052230</keyword>
  <keyword>docetaxel</keyword>
  <keyword>FGFR</keyword>
  <keyword>carboplatin</keyword>
  <keyword>HGS1036</keyword>
  <keyword>squamous non-small cell lung cancer</keyword>
  <keyword>paclitaxel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

